Previous 10 | Next 10 |
2023-11-05 23:46:57 ET In the upcoming week of November, investors can anticipate a flurry of quarterly reports from major companies, promising significant market activity. Notable among them is Disney ( NYSE: DIS ), a household name set to disclose its financial performance. ...
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the t...
2023-11-02 10:01:01 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in F...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
CareDx Inc. (CDNA) is expected to report $-0.67 for Q3 2023
2023-11-01 16:21:38 ET More on CareDx CareDx: Diversification Strategies Vs. Core Weaknesses CareDx, Inc. (CDNA) Q2 2023 Earnings Call Transcript Natera prevails in patent battle as Supreme Court denies CareDx appeal CareDx upgraded at Raymond James on favora...
Board Establishes Office of the CEO, Conducts Search for Successor Raises 2023 Revenue Guidance CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare so...
2023-10-23 17:42:52 ET Gainers: Redfin ( RDFN ) +15% . Agilysys ( AGYS ) +11% . Medpace Holdings ( MEDP ) +5% . HomeStreet ( HMST ) +5% . IDEAYA Biosciences ( IDYA ) +5% . Losers: CareDx ( CDNA ) -8% . A...
Demonstrates Breadth of Offerings for HLA Laboratories and Validation of AlloSeq HCT CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transpl...
2023-10-11 06:08:56 ET Summary CareDx faces revenue decline and Medicare billing challenges, despite a strong balance sheet and diversified revenue streams. High institutional ownership and a looming patent expiration for AlloMap add layers of complexity and risk. Investment R...
News, Short Squeeze, Breakout and More Instantly...
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the s...
2024-06-20 11:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Surveillance Monitoring with Both AlloSure Kidney and the AlloView AI-Enabled Risk Prediction Model Improves the Detection of All Types of Allograft Rejection AlloSure Kidney Detected Subclinical Rejection in Clinically Stable Patients and AlloSure Kidney dd-cfDNA Levels were Elevated Pri...